Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657280 · ClinicalTrials.gov registry record · Early Phase 1
Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT00657280: Completed Early Phase 1 study, sponsored by Stanford University.
NCT00657280 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00657280, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. This study will also investigate the effect of sitagliptin on the body's use of sugar, and of the effect of sitagliptin on blood flow to the heart.
Interventions
- DRUG Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657280
The ClinicalTrials.gov registry entry for NCT00657280 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sitagliptin is the first listed.
NCT00657280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657280 about?
NCT00657280 is a clinical study titled "Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure". This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blo...
What is the current status of trial NCT00657280?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2008-04. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00657280?
The interventions under investigation include: Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00657280?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.